RevBio receives NIH grant to explore the treatment of VCFs with its regenerative bone adhesive technology

774

RevBio has been awarded a phase one small business innovation research grant from the National Institute on Aging, part of the National Institutes of Health (NIH), which will allow the company to pursue the treatment of vertebral compression fractures (VCFs) with its patented bone adhesive technology, Tetranite.

Due to the fact that the osteoconductive bone adhesive is injectable, the material can be delivered in minimally invasive procedures, say RevBio.

Kevin Foley, professor of neurosurgery, orthopaedic surgery, and biomedical engineering at the University of Tennessee Health Science Center (Memphis, USA), said: “The adhesive and structural features of this biomaterial combined with the fact that it is osteoconductive and ultimately replaced by bone make it an excellent candidate for an improved vertebroplasty procedure

“This regenerative, adhesive, and cohesive material delivered percutaneously could significantly improve the way these fractures are treated.”

Brian Hess, CEO of RevBio, added: “This opportunity complements the indications we are currently pursuing in dentistry, cranial surgery, orthopaedic trauma procedures, and animal health indications.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here